United Therapeutics Corporation (UTHR)
NASDAQ: UTHR · Real-Time Price · USD
359.58
-0.58 (-0.16%)
Dec 20, 2024, 4:00 PM EST - Market closed
United Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 2,756 | 2,328 | 1,936 | 1,686 | 1,483 | 1,449 | Upgrade
|
| Revenue | 2,756 | 2,328 | 1,936 | 1,686 | 1,483 | 1,449 | Upgrade
|
| Revenue Growth (YoY) | 25.04% | 20.20% | 14.88% | 13.63% | 2.38% | -11.00% | Upgrade
|
| Cost of Revenue | 304.8 | 257.5 | 151.6 | 122.5 | 108.1 | 117.6 | Upgrade
|
| Gross Profit | 2,451 | 2,070 | 1,785 | 1,563 | 1,375 | 1,331 | Upgrade
|
| Selling, General & Admin | 607.2 | 476 | 472.8 | 466.1 | 421.1 | 335 | Upgrade
|
| Research & Development | 498.6 | 408 | 322.9 | 410 | 357.7 | 1,174 | Upgrade
|
| Operating Expenses | 1,106 | 884 | 795.7 | 876.1 | 778.8 | 1,509 | Upgrade
|
| Operating Income | 1,346 | 1,186 | 989 | 686.9 | 596.4 | -177.6 | Upgrade
|
| Interest Expense | -50.1 | -59.3 | -32.4 | -18.6 | -23.5 | -44.2 | Upgrade
|
| Interest & Investment Income | 200.8 | 162.7 | 45.2 | 16.7 | 28.6 | 44.2 | Upgrade
|
| Other Non Operating Income (Expenses) | -28.4 | -27.3 | -74.2 | 43.8 | 26.4 | 20.2 | Upgrade
|
| EBT Excluding Unusual Items | 1,468 | 1,262 | 927.6 | 728.8 | 627.9 | -157.4 | Upgrade
|
| Gain (Loss) on Sale of Investments | 38.7 | 15.8 | 34.2 | -2.3 | 16.4 | 1.2 | Upgrade
|
| Asset Writedown | -3.6 | -3.6 | -11.2 | -132.6 | -5.4 | -8.8 | Upgrade
|
| Pretax Income | 1,438 | 1,274 | 950.6 | 593.9 | 638.9 | -165 | Upgrade
|
| Income Tax Expense | 327 | 289.5 | 223.3 | 118.1 | 124.1 | -60.5 | Upgrade
|
| Net Income | 1,111 | 984.8 | 727.3 | 475.8 | 514.8 | -104.5 | Upgrade
|
| Net Income to Common | 1,111 | 984.8 | 727.3 | 475.8 | 514.8 | -104.5 | Upgrade
|
| Net Income Growth | 23.46% | 35.40% | 52.86% | -7.58% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 46 | 47 | 46 | 45 | 44 | 44 | Upgrade
|
| Shares Outstanding (Diluted) | 49 | 50 | 49 | 47 | 45 | 44 | Upgrade
|
| Shares Change (YoY) | -1.36% | 2.47% | 2.54% | 6.05% | 1.83% | -0.45% | Upgrade
|
| EPS (Basic) | 24.28 | 21.04 | 15.98 | 10.60 | 11.65 | -2.39 | Upgrade
|
| EPS (Diluted) | 22.72 | 19.81 | 15.00 | 10.06 | 11.54 | -2.39 | Upgrade
|
| EPS Growth | 25.10% | 32.07% | 49.11% | -12.82% | - | - | Upgrade
|
| Free Cash Flow | 898.1 | 747.6 | 663.7 | 477.4 | 696.4 | -290.3 | Upgrade
|
| Free Cash Flow Per Share | 18.38 | 15.04 | 13.68 | 10.09 | 15.61 | -6.63 | Upgrade
|
| Gross Margin | 88.94% | 88.94% | 92.17% | 92.73% | 92.71% | 91.88% | Upgrade
|
| Operating Margin | 48.82% | 50.96% | 51.08% | 40.75% | 40.21% | -12.26% | Upgrade
|
| Profit Margin | 40.31% | 42.31% | 37.56% | 28.23% | 34.71% | -7.21% | Upgrade
|
| Free Cash Flow Margin | 32.58% | 32.12% | 34.28% | 28.32% | 46.95% | -20.04% | Upgrade
|
| EBITDA | 1,412 | 1,239 | 1,040 | 736.8 | 646.3 | -131.7 | Upgrade
|
| EBITDA Margin | 51.23% | 53.24% | 53.73% | 43.71% | 43.57% | -9.09% | Upgrade
|
| D&A For EBITDA | 66.5 | 53.2 | 51.3 | 49.9 | 49.9 | 45.9 | Upgrade
|
| EBIT | 1,346 | 1,186 | 989 | 686.9 | 596.4 | -177.6 | Upgrade
|
| EBIT Margin | 48.82% | 50.96% | 51.08% | 40.75% | 40.21% | -12.26% | Upgrade
|
| Effective Tax Rate | 22.74% | 22.72% | 23.49% | 19.89% | 19.42% | - | Upgrade
|
| Revenue as Reported | - | - | - | - | - | 1,449 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.